Canaccord Genuity analyst Aravinda Galappatthige downgraded Thomson Reuters (TRI – Research Report) to Hold today and set a price target of $108.00. The company’s shares closed last Friday at $111.08, close to its 52-week high of $113.12.
According to TipRanks.com, Galappatthige is a 4-star analyst with an average return of 6.1% and a 54.4% success rate. Galappatthige covers the Services sector, focusing on stocks such as Cogeco Communications, Corus Entertainment, and Shaw Communications.
Currently, the analyst consensus on Thomson Reuters is a Moderate Buy with an average price target of $110.47, representing a -0.2% downside. In a report released today, National Bank also downgraded the stock to Hold with a C$145.00 price target.
The company has a one-year high of $113.12 and a one-year low of $69.50. Currently, Thomson Reuters has an average volume of 375.6K.
Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Thomson Reuters Corporation is a multinational media conglomerate which engages in providing news and business information services to professionals. It offers value-added information and technology to users in the fields of accounting, financial services, law, tax, corporate training and assessment, reference information, higher education, scientific research and healthcare.
Read More on TRI:
- Transdigm Group (TDG): New Buy Recommendation for This Technology Giant
- Enanta Pharmaceuticals (ENTA) Receives a Buy from JMP Securities
- JMP Securities Believes OrthoPediatrics (KIDS) Still Has Room to Grow
- JMP Securities Thinks Confluent’s Stock is Going to Recover
- Leerink Partners Maintains a Buy Rating on Progyny (PGNY)